Abcam vs Alloy Therapeutics
Abcam vs Alloy Therapeutics, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Abcam is on 61/100 and Alloy Therapeutics on 51/100.
Where each one leads
Abcam
- our overall score: 61/100 against 51/100
- domain rating: 72/100 against 47/100
- funding raised: $257M against $157M
Alloy Therapeutics
- agent readiness: 39/100 against 22/100
At a glance
| Measure | Abcam | Alloy Therapeutics |
|---|---|---|
| What it is | Global supplier of life science research tools, including antibodies, reagents, and assays. | A biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services. |
| Category | Biotechnology, Life Sciences, Discovery Tools, Antibodies | Biotechnology, Artificial Intelligence, Drug Discovery, Drug Development |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 1998 | 2017 |
| Headquarters | Cambridge, United Kingdom | Boston, USA |
| Status | Active | Active |
Size, funding and growth
| Measure | Abcam | Alloy Therapeutics |
|---|---|---|
| Total funding | $257M | $157M |
| Latest round | Series D | Series E |
| Valuation | Not published | $1.0B |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Abcam | Alloy Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 61/100 | 51/100 |
| Traction | 40/100 | 40/100 |
| Team | 70/100 | 30/100 |
| Community | 15/100 | Not published |
| Search visibility | 16/100 | 15/100 |
| Quality | 78/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (22/100) | F (39/100) |
| Domain ratingLink authority, 0-100 | 72/100 | 47/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Abcam | Alloy Therapeutics |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Tag Manager |
| Support stack | Not detected | HubSpot |
Abcam vs Alloy Therapeutics: common questions
Which is better, Abcam or Alloy Therapeutics?
On our 0-100 score Abcam rates higher (61/100 against 51/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do Abcam and Alloy Therapeutics compare on the numbers?
Abcam leads on our overall score (61/100 against 51/100), domain rating (72/100 against 47/100), funding raised ($257M against $157M). Alloy Therapeutics leads on agent readiness (39/100 against 22/100).
Read the full Abcam review and pricing or the Alloy Therapeutics review and pricing. You can also browse other Abcam alternatives we track.